SciELO - Scientific Electronic Library Online

 
vol.8 número1Factores que inciden en el citodiagnóstico no útil. Policlínico "5 de Septiembre". Consolación del Sur. Enero-diciembre 2002Una opción terapéutica exitosa para la osteomielitis crónica en condiciones de escasos recursos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista de Ciencias Médicas de Pinar del Río

versión On-line ISSN 1561-3194

Resumen

SUAREZ ESPINOSA, Ileana  y  VALDES CARRILLO, Ramón. Lipid profile and menstrual disorders in women using contraceptive injection combined Mesigyne. Rev Ciencias Médicas [online]. 2004, vol.8, n.1, pp. 53-62. ISSN 1561-3194.

Hormonal contraception with long-acting hormonal injections represrnt an established alternative. This study was aimed at knowing the disturbances that mently-birth control injection combined with mesigyna scherring AG provoked over lipid metabolism and menstrual pattern, to investigate it, 75 non-pregnant women who wished to control their fertility were included in the study. Total cholesterol, C-HDL, C-LDL, triglycerides and Ipa were determined showing that C-HDL had a slightly increase-trend from the second year of the use of AICs Mesigyna, the Lpa increased in the 16% of the total of patients. Menstrual pattern had regularity in its cycle-81.3 % of the total of women at the end of the study- concluding that the use of AICs Mesigyna produces disturbances on menstrual cycle invariably, demonstrating its antiatherogenic role due to its metabolic effects over lipid profile.

Palabras clave : CONTRACEPTION; BIRTH CONTROL; LIPIDS; LIPOPROTEINS.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License